已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

医学 血压 危险系数 糖尿病 2型糖尿病 心肌梗塞 心力衰竭 内科学 心脏病学 冲程(发动机) 安慰剂 比例危险模型 急诊医学 重症监护医学 置信区间 内分泌学 机械工程 替代医学 病理 工程类
作者
Milad Nazarzadeh,Zeinab Bidel,Dexter Canoy,Emma Copland,Derrick Bennett,Abbas Dehghan,George Davey Smith,Rury R. Holman,Mark Woodward,Ajay Gupta,Amanda Adler,Małgorzata Wamil,Naveed Sattar,William C. Cushman,Richard J. McManus,Koon Teo,Barry R. Davis,John Chalmers,Carl J. Pepine,Kazem Rahimi,Larry Agodoa,Ale Algra,Folkert W. Asselbergs,Nigel Beckett,Eivind Berge,Henry R. Black,Frank P. Brouwers,Morris J. Brown,Christopher J. Bulpitt,Bob Byington,J A Cutler,Richard B. Devereaux,Jamie P. Dwyer,R Estacio,Robert Fagard,Kim Fox,Tomohiro FUKUI,Yutaka Imai,Masao Ishii,Stevo Julius,Yoshihiko Kanno,Sverre E. Kjeldsen,John B. Kostis,K Kuramoto,Jan Lanke,Edmund J. Lewis,Julia B. Lewis,Michel Lièvre,Lars Lindholm,Stephan Lueders,Stephen MacMahon,Giuseppe Mancia,M Matsuzaki,Maria H. Mehlum,Steven Nissen,Hiroshi Ogawa,Toshio Ogihara,Takayoshi Ohkubo,C. Palmer,Anushka Patel,Marc Allan Pfeffer,Neil R Poulter,Hiromi Rakugi,Gianpaolo Reboldi,Christopher M. Reid,Giuseppe Remuzzi,Piero Ruggenenti,T Saruta,Joachim Schrader,Robert W. Schrier,Peter Sever,Peter Sleight,Jan A. Staessen,Hiromichi Suzuki,Lutgarde Thijs,Kenji Ueshima,Seiji Umemoto,Wiek H. van Gilst,Paolo Verdecchia,Kristian Wachtell,Paul K. Whelton,Lindon Wing,Yoshiki Yui,Salim Yusuf,Alberto Zanchetti,Z Y Zhang,Craig S. Anderson,Colin Baigent,Brenner Bm,Rory Collins,Dick de Zeeuw,Jacobus Lubsen,Ettore Malacco,Bruce Neal,Vlado Perkovic,Bertram Pitt,Anthony Rodgers,Peter M. Rothwell,Gholamreza Salimi‐Khorshidi,Johan Sundström,F. Turnbull,Giancarlo Viberti,J Wang
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:10 (9): 645-654 被引量:45
标识
DOI:10.1016/s2213-8587(22)00172-3
摘要

Summary

Background

Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events by type 2 diabetes status, as well as by baseline levels of systolic blood pressure.

Methods

We conducted a one-stage individual participant-level data meta-analysis of major randomised controlled trials using the Blood Pressure Lowering Treatment Trialists' Collaboration dataset. Trials with information on type 2 diabetes status at baseline were eligible if they compared blood pressure-lowering medications versus placebo or other classes of blood pressure-lowering medications, or an intensive versus a standard blood pressure-lowering strategy, and reported at least 1000 persons-years of follow-up in each group. Trials exclusively on participants with heart failure or with short-term therapies and acute myocardial infarction or other acute settings were excluded. We expressed treatment effect per 5 mm Hg reduction in systolic blood pressure on the risk of developing a major cardiovascular event as the primary outcome, defined as the first occurrence of fatal or non-fatal stroke or cerebrovascular disease, fatal or non-fatal ischaemic heart disease, or heart failure causing death or requiring hospitalisation. Cox proportional hazard models, stratified by trial, were used to estimate hazard ratios (HRs) separately by type 2 diabetes status at baseline, with further stratification by baseline categories of systolic blood pressure (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg). To estimate absolute risk reductions, we used a Poisson regression model over the follow-up duration. The effect of each of the five major blood pressure-lowering drug classes, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β blockers, calcium channel blockers, and thiazide diuretics, was estimated using a network meta-analysis framework. This study is registered with PROSPERO, CRD42018099283.

Findings

We included data from 51 randomised clinical trials published between 1981 and 2014 involving 358 533 participants (58% men), among whom 103 325 (29%) had known type 2 diabetes at baseline. The baseline mean systolic/diastolic blood pressure of those with and without type 2 diabetes was 149/84 mm Hg (SD 19/11) and 153/88 mm Hg (SD 21/12), respectively. Over 4·2 years median follow-up (IQR 3·0–5·0), a 5 mm Hg reduction in systolic blood pressure decreased the risk of major cardiovascular events in both groups, but with a weaker relative treatment effect in participants with type 2 diabetes (HR 0·94 [95% CI 0·91–0·98]) compared with those without type 2 diabetes (0·89 [0·87–0·92]; pinteraction=0·0013). However, absolute risk reductions did not differ substantially between people with and without type 2 diabetes because of the higher absolute cardiovascular risk among participants with type 2 diabetes. We found no reliable evidence for heterogeneity of treatment effects by baseline systolic blood pressure in either group. In keeping with the primary findings, analysis using stratified network meta-analysis showed no evidence that relative treatment effects differed substantially between participants with type 2 diabetes and those without for any of the drug classes investigated.

Interpretation

Although the relative beneficial effects of blood pressure reduction on major cardiovascular events were weaker in participants with type 2 diabetes than in those without, absolute effects were similar. The difference in relative risk reduction was not related to the baseline blood pressure or allocation to different drug classes. Therefore, the adoption of differential blood pressure thresholds, intensities of blood pressure lowering, or drug classes used in people with and without type 2 diabetes is not warranted.

Funding

British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
funny完成签到 ,获得积分10
刚刚
charint完成签到,获得积分10
1秒前
我去吃饭完成签到 ,获得积分10
2秒前
默mo完成签到 ,获得积分10
2秒前
4秒前
charint发布了新的文献求助10
4秒前
jedeecn完成签到,获得积分20
6秒前
曾经的帅哥完成签到,获得积分10
6秒前
Anna完成签到 ,获得积分10
6秒前
汉堡包的应助被richardhipower采纳,获得10
6秒前
日出前完成签到 ,获得积分10
7秒前
谦让夏山完成签到 ,获得积分10
7秒前
酸菜爱生活完成签到 ,获得积分10
7秒前
10秒前
千诺完成签到 ,获得积分10
10秒前
淡然雁梅完成签到 ,获得积分10
10秒前
倪妮完成签到 ,获得积分10
11秒前
科研通AI6.2的应助被iceicefdtd采纳,获得10
11秒前
bluemoon发布了新的文献求助10
11秒前
Lee完成签到 ,获得积分10
12秒前
大模型的应助被221008zn采纳,获得10
12秒前
jiuzhege完成签到 ,获得积分10
13秒前
我想进步完成签到,获得积分10
14秒前
baolong完成签到,获得积分10
14秒前
15秒前
harry完成签到,获得积分10
16秒前
16秒前
16秒前
烟花的应助被小豆包采纳,获得10
16秒前
冷静新烟完成签到,获得积分10
16秒前
解惑大师完成签到 ,获得积分10
17秒前
深情安青的应助被richardhipower采纳,获得10
17秒前
鲁大海完成签到,获得积分10
18秒前
知性的夏之完成签到 ,获得积分10
18秒前
墨白完成签到,获得积分10
19秒前
欢喜的文轩完成签到 ,获得积分10
19秒前
初椿完成签到 ,获得积分10
20秒前
典雅的皓轩完成签到 ,获得积分10
21秒前
子皿完成签到,获得积分10
21秒前
xiankanyun完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189866
求助须知:如何正确求助?哪些是违规求助? 9577019
关于积分的说明 21851254
捐赠科研通 7787798
什么是DOI,文献DOI怎么找? 3435795
关于科研通互助平台的介绍 2559856
邀请新用户注册赠送积分活动 2482699